

DAFTAR PUSTAKA

- Afdhal, N., Mchutchison, J., Brown, R., Jacobson, I., Manns, M., Poordad, F., Weksler, B., Esteban, R., 2008. Thrombocytopenia associated with chronic liver disease. *J. Hepatol.* 48, 1000–1007. <https://doi.org/10.1016/j.jhep.2008.03.009>
- Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M.A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., Artaman, A., Ayele, T.A., Barac, A., Bensenor, I., Berhane, A., Bhutta, Z., Castillo-Rivas, J., Chitheer, A., Choi, J.-Y., Cowie, B., Dandona, L., Dandona, R., Dey, S., Dicker, D., Phuc, H., Ekwueme, D.U., Zaki, M.E.S., Fischer, F., Fürst, T., Hancock, J., Hay, S.I., Hotez, P., Jee, S.H., Kasaeian, A., Khader, Y., Khang, Y.-H., Kumar, G.A., Kutz, M., Larson, H., Lopez, A., Lunevicius, R., Malekzadeh, R., McAlinden, C., Meier, T., Mendoza, W., Mokdad, A., Moradi-Lakeh, M., Nagel, G., Nguyen, Q., Nguyen, G., Ogbo, F., Patton, G., Pereira, D.M., Pourmalek, F., Qorbani, M., Radfar, A., Roshandel, G., Salomon, J.A., Sanabria, J., Sartorius, B., Satpathy, M., Sawhney, M., Sepanlou, S., Shackelford, K., Shore, H., Sun, J., Mengistu, D.T., Topór-Madry, R., Tran, B., Ukwaja, K.N., Vlassov, V., Vollset, S.E., Vos, T., Wakayo, T., Weiderpass, E., Werdecker, A., Yonemoto, N., Younis, M., Yu, C., Zaidi, Z., Zhu, L., Murray, C.J.L., Naghavi, M., Fitzmaurice, C., 2017. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level. *JAMA Oncol.* 98121, 1683–1691. <https://doi.org/10.1001/jamaoncol.2017.3055>
- Akkiz, H., Carr, B.I., Yalçın K., K., Guerra, V., Kuran, S., Altıntaş, E., Üsküdar, O., Karaoğullarından, Ü., Özakyol, A., Tokmak, S., Yücesoy, M., Bahçeci, H.İ., Ülkü, A., Akçam, T., Yalçın Polat, K., Ekinci, N., Şimşek, H., Örmeci, N., Sonsuz, A., Demir, M., Kılıç, M., Uygun, A., Ballı, T., Demir, A., Arslan, B., Doran, F., 2018. Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients. *Oncology* 94, 116–124. <https://doi.org/10.1159/000484564>
- American Cancer Society, 2016. What Is Liver Cancer? Benign liver tumors Hepatic adenoma [WWW Document]. URL <https://www.cancer.org/cancer/liver-cancer/about/what-is-liver-cancer.html> (diakses 2.13.18).
- Ananthkrishnan, A., Gogineni, V., Saeian, K., 2006. Epidemiology of Primary and Secondary Liver Cancers. *Semin. Intervent. Radiol.* 23, 047–063. <https://doi.org/10.1055/s-2006-939841>
- Andrade, L. de O., D'Oliveira, A., Melo, R., De Souza, E., Silva, C.C., Parana, R., 2009. Association between hepatitis C and hepatocellular carcinoma. *J. Glob. Infect. Dis.* 1, 33. <https://doi.org/10.4103/0974-777X.52979>
- Attwa, M.H., El-Etreby, S.A., 2015. Guide for diagnosis and treatment of hepatocellular carcinoma. *World J. Hepatol.* 7, 1632–1651. <https://doi.org/10.4254/wjh.v7.i12.1632>
- Bernardi, M., Ricci, C.S., Zaccherini, G., 2014. Role of Human Albumin in the Management of Complications of Liver Cirrhosis. *J. Clin. Exp. Hepatol.* 4, 302–311. <https://doi.org/10.1016/j.jceh.2014.08.007>

- Bialecki, E.S., Di Bisceglie, A.M., 2005. Diagnosis of hepatocellular carcinoma. *Hpb* 7, 26–34. <https://doi.org/10.1080/13651820410024049>
- Birgegård, G., Aapro, M.S., Bokemeyer, C., Dicato, M., Drings, P., Hornedo, J., Krzakowski, M., Ludwig, H., Pecorelli, S., Schmoll, H., Schneider, M., Schrijvers, D., Shasha, D., Van Belle, S., 2005. Cancer-related anemia: Pathogenesis, prevalence and treatment. *Oncology* 68, 3–11. <https://doi.org/10.1159/000083128>
- Blasi, A., 2015. Coagulopathy in liver disease : Lack of an assessment tool. *World J. Gastroenterol.* 21, 10062–10071. <https://doi.org/10.3748/wjg.v21.i35.10062>
- Bruix, J., Sherman, M., 2011. Management of hepatocellular carcinoma: An update. *Hepatology* 53, 1020–1022. <https://doi.org/10.1002/hep.24199>
- Cabibbo, G., Maida, M., Genco, C., Parisi, P., Peralta, M., Antonucci, M., Brancatelli, G., Cammà, C., Craxì, A., Marco, V. Di, Cabibbo, G., Maida, M., Genco, C., Peralta, M., Antonucci, M., Brancatelli, G., Cammà, C., Craxì, A., Marco, V. Di, 2012. Natural history of untreatable hepatocellular carcinoma : A retrospective cohort study. *World J. Hepatol.* 4, 256–261. <https://doi.org/10.4254/wjh.v4.i9.256>
- Carr, B.I., 2010. Tumors of the Liver and Biliary Tree, in: *Harrison's Principle of Internal Medicine 18th Edition*. McGraw-Hill, New York, hal. 517–527.
- Carr, B.I., Guerra, V., 2017. Serum Albumin Levels in Relation to Tumor Parameters in Hepatocellular Carcinoma Patients. *Int. J. Biol. Markers* 32, 391–396. <https://doi.org/10.5301/ijbm.5000300>
- Carr, B.I., Guerra, V., 2013. Thrombocytosis and hepatocellular carcinoma. *Dig. Dis. Sci.* 58, 1790–1796. <https://doi.org/10.1007/s10620-012-2527-3>
- Carr, B.I., Guerra, V., Giannini, E.G., Farinati, F., Ciccarese, F., Ludovico Rapaccini, G., Di Marco, M., Benvegnù, L., Zoli, M., Borzio, F., Caturelli, E., Chiaramonte, M., Trevisani, F., 2014. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. *Semin. Oncol.* 41, 252–258. <https://doi.org/10.1053/j.seminoncol.2014.03.006>
- Castillo, J.J., Vincent, M., Justice, E., 2012. Diagnosis and Management of Hyponatremia in Cancer Patients. *Oncologist* 17, 756–765.
- Cheng, S.-B., Liu, H.-T., Lin, P.-T., Lai, C.-Y., Huang, Y.-C., 2016. Folate and vitamin B-6 status are not associated with homocysteine, oxidative stress and antioxidant capacities in patients with hepatocellular carcinoma. *Eur. J. Clin. Nutr.* 70, 855.
- Dicato, M., 2003. Anemia in Cancer : Some Pathophysiological Aspects. *Oncologist* 8, 19–21.
- Donato, F., Tagger, A., Gelatti, U., Parrinello, G., Boffetta, P., Albertini, A., Decarli, A., Trevisi, P., Ribero, M.L., 2002. Alcohol and Hepatocellular Carcinoma: The Effect of Lifetime Intake and Hepatitis B Virus Infections in Men and Women. *Am. J. Epidemiol.* 155, 323–331.
- Dufour, J.F., Greten, T.F., Raymond, E., Roskams, T., De, T., Ducreux, M., Mazzaferro, V., Governing, E., 2012. Clinical Practice Guidelines EASL – EORTC Clinical Practice Guidelines : Management of hepatocellular carcinoma European Organisation for Research and Treatment of Cancer. J.

- Hepatol. 56, 908–43. <https://doi.org/10.1016/j.jhep.2011.12.001>
- El-Bahrawy, M., 2010. Alpha-fetoprotein-producing non-germ cell tumours of the female genital tract. *Eur. J. Cancer* 46, 1317–1322. <https://doi.org/10.1016/j.ejca.2010.01.028>
- Fateen, W., Ryder, S.D., 2017. Screening for hepatocellular carcinoma: patient selection and perspectives. *J. Hepatocell. carcinoma* 4, 71–79. <https://doi.org/10.2147/JHC.S105777>
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., 2015. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int. J. Cancer* 136, E359–E386. <https://doi.org/10.1002/ijc.29210>
- Finkelmeier, F., Bettinger, D., Koberle, V., Schultheiß, M., Zeuzem, S., Kronenberger, B., Piiper, A., Waidmann, O., 2014. Single measurement of hemoglobin predicts outcome of HCC patients. *Med. Oncol.* 31, 1–8. <https://doi.org/10.1007/s12032-013-0806-2>
- Fornier, A., Reig, M., Bruix, J., 2018. Hepatocellular carcinoma. *Lancet* 391, 1301–1314. [https://doi.org/10.1016/S0140-6736\(18\)30010-2](https://doi.org/10.1016/S0140-6736(18)30010-2)
- Fujiwara, Y., Shiba, H., Furukawa, K., Iida, T., Sakamoto, T., Gocho, T., Wakiyama, S., Hirohara, S., Ishida, Y., Misawa, T., Ohashi, T., Yanaga, K., 2010. Perioperative change in white blood cell count predicts outcome of hepatic resection for hepatocellular carcinoma. *J. Hepatobiliary. Pancreat. Sci.* 17, 892–897. <https://doi.org/10.1007/s00534-010-0290-4>
- Gaglio, P., Marfo, K., Chiodo, J., 2012. Hyponatremia in Cirrhosis and End-Stage Liver Disease : Treatment with the Vasopressin V₂ -Receptor Antagonist Tolvaptan. *Dig. Dis. Sci.* 57, 2774–2785. <https://doi.org/10.1007/s10620-012-2276-3>
- Ghouri, Y.A., Mian, I., Rowe, J.H., 2017. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. *J. Carcinog.* 16. https://doi.org/10.4103/jcar.JCar_9_16
- Giannini, E.G., 2006. Review article : thrombocytopenia in chronic liver disease and pharmacologic treatment options. *Aliment. Pharmacol. % Ther.* 23, 1055–1065. <https://doi.org/10.1111/j.1365-2036.2006.02889.x>
- Goh, G.B., Li, J.W., Chang, P., Chow, K., Tan, C., 2017. Deciphering the Epidemiology of Hepatocellular Carcinoma Through the Patients Across 3 Decades. *Hepatol. Commun.* 1, 564–571. <https://doi.org/10.1002/hep4.1059>
- Gowda, S., Desai, P.B., Kulkarni, S.S., Hull, V. V, Math, A.A.K., Vernekar, S.N., 2010. Markers of renal function tests. *N. Am. J. Med. Sci.* 2, 170–173.
- Goyal, H., Hu, Z., 2017. Prognostic value of red blood cell distribution width in hepatocellular carcinoma. *Ann. Transl. Med.* 5, 1–5. <https://doi.org/10.21037/atm.2017.06.30>
- Hall, P., Cash, J., 2012. What is the Real Function of the Liver ‘ Function ’ Tests ? *Ulster Med. J.* 81, 30–36.
- Hameed, A., Naeem, S., Shaikh, A.S., Khurshed, I., Hamid, A., Naveed, I.A., 2006. An Assessment of Coagulation Parameters in Liver Cirrhosis. *Biomedica* 22, 74–77.
- International Agency for Research on Cancer, 2018. GLOBOCAN 2012:

- Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 [WWW Document]. URL http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
- Keng, V.W., Largaespada, D.A., Villanueva, A., 2012. Why men are at higher risk for hepatocellular carcinoma? *J. Hepatol.* 57, 453–454. <https://doi.org/10.1016/j.jhep.2012.03.004>
- Kikuchi, L., Chagas, A., Alencar, R., Tani, C., Diniz, M., D’Albuquerque, L., Carrilho, F., 2017. Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage. *Clinics* 72, 454–460. [https://doi.org/10.6061/clinics/2017\(08\)01](https://doi.org/10.6061/clinics/2017(08)01)
- Kim, W.R., Flamm, S.L., Bisceglie, A.M. Di, Bodenheimer, H.C., 2008. Serum Activity of Alanine Aminotransferase (ALT) as an Indicator of Health and Disease. *Hepatology* 47, 1363–1370. <https://doi.org/10.1002/hep.22109>
- Knight, K., Wade, S., Balducci, L., 2004. Prevalence and Outcomes of Anemia in Cancer : A Systematic Review of the Literature. *Am. J. Med.* 116, 11S–26S. <https://doi.org/10.1016/j.amjmed.2003.12.008>
- Koda, M., Murawaki, Y., Hirooka, Y., Kitamoto, M., Ono, M., Sakaeda, H., Joko, K., Sato, S., Tamaki, K., Yamasaki, T., Shibata, H., Shimoe, T., Matsuda, T., Toshikuni, N., Fujioka, S.I., Ohmoto, K., Nakamura, S., Kariyama, K., Aikata, H., Kobayashi, Y., Tsutsui, A., 2012. Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16346 treated nodules in 13283 patients. *Hepatol. Res.* 42, 1058–1064. <https://doi.org/10.1111/j.1872-034X.2012.01025.x>
- Kojiro, M., Wanless, I.R., Alves, V., Badve, S., Balabaud, C., Bedosa, P., Bhathal, P., Bioulac-Sage, P., Brunt, E.M., Burt, A.D., Craig, J.R., Dhillon, A., Ferrell, L., Geller, S.A., Goodman, Z.D., Gouw, A.S.H., Guido, M., Guindi, M., Hytiroglou, P., Kage, M., Kondo, F., Kudo, M., Lauwers, G.Y., Nakano, M., Paradis, V., Park, Y.N., Quaglia, A., Roncalli, M., Roskams, T., Ruebner, B., Sakamoto, M., Saxena, R., Theise, N.D., Thung, S., Taniakos, D., 2009. Pathologic diagnosis of early hepatocellular carcinoma: A report of the International Consensus Group for Hepatocellular Neoplasia. *Hepatology* 49, 658–664. <https://doi.org/10.1002/hep.22709>
- Ladenheim, M.R., Kim, N.G., Nguyen, P., Le, A., Stefanick, M.L., Garcia, G., Nguyen, M.H., 2016. Sex differences in disease presentation , treatment and clinical outcomes of patients with hepatocellular carcinoma : a single-centre cohort study. *BMJ Open Gastroenterol.* 3, 1–8. <https://doi.org/10.1136/bmjgast-2016-000107>
- Lahoti, A., Humphreys, B.D., 2016. Chapter 3 : AKI Associated With Malignancies. *Am. Soc. Nephrol.* 1–8.
- Lechner, K., Niessner, H., Thaler, E., 2008. Coagulation Abnormalities in Liver Disease. *Semin. Thromb. Hemost.* 4, 40–56.
- Limijadi, E.K.S., Suromo, L.B., Budiwiyo, I., 2016. Prothrombin and activated partial thromboplastin time are prolonged in hepatic cirrhosis. *Universa Med.* 35, 26–32. <https://doi.org/10.18051/UnivMed.2016.v35.26-74>
- Liu, P., Xie, S., Hu, S., Cheng, X., Gao, T., Zhang, C., 2017. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States.

- Oncotarget 8, 68131–68137.
- Longo, D.L., Kasper, D.L., Jameson, L.J., Fauci, A.S., Hauser, S.L., Loscalzo, J., 2012. Harrison's Principles of Internal Medicine 18th Edition.
- Lopez, J., Balasegaram, M., Thambyrajah, V., Timor, J., 1996. The value of Liver Function Tests in Hepatocellular Carcinoma. *Malays. J. Pathol.*
- Marcassoli, L., Pirola, M., Gregorio, P. Di, D, B.S., Buccino, G., D, B.S., 1991. Ascitic Fluid Analysis in Hepatocellular Carcinoma. *Cancer* 72, 677–682.
- Marrero, J.A., Kudo, M., Bronowicki, J.-P., 2010. The challenge of prognosis and staging for hepatocellular carcinoma. *Oncologist* 15, 23–33. <https://doi.org/10.1634/theoncologist.2010-S4-23>
- McPherson, R.A., Pincus, M.R., 2011. Henry's Clinical Diagnosis and Management by Laboratory Methods, 22nd ed. Elsevier, Philadelphia.
- Nishikawa, H., Kita, R., Kimura, T., Ohara, Y., Sakamoto, A., Saito, S., 2015. Hyponatremia in Hepatocellular Carcinoma Complicating with Cirrhosis. *J. Cancer* 6, 482–489. <https://doi.org/10.7150/jca.11665>
- Oken, M., Creech, R., Tormey, D., Horton, J., Davis, T., McFadden, E., Carbone, P., 1982. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am. J. Clin. Oncol.* <https://doi.org/10.1097/00000421-198212000-00014>
- Pang, Q., Qu, K., Zhang, J.-Y., Song, S.-D., Liu, S.-S., Tai, M.-H., Liu, H.-C., Liu, C., 2015. The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma. *Medicine (Baltimore)*. 94, 1–11. <https://doi.org/10.1097/MD.0000000000001431>
- Parkin, D.M., Ohshima, H., Srivatanakul, P., Vatanasapt, V., 1993. Cholangiocarcinoma: Epidemiology, Mechanisms Carcinogenesis and Prevention of. *Cancer Epidemiol. Biomarkers Prev.* 2, 537–544.
- Peck-Radosavljevic, M., 2000. Thrombocytopenia in liver disease. *Can. J. Gastroenterol.* 14, 60D–66D.
- Peng, Y., Goyal, H., Xu, G., 2017. Serum bilirubin has an important role in multiple clinical applications. *J. Lab. Precis. Med.* 2, 1–7. <https://doi.org/10.21037/jlpm.2017.09.08>
- Qiu, M., Xu, R., Ruan, D., Li, Z., Luo, H., Teng, K., Wang, Z., Li, Y., Jiang, W., 2010. Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China. *Tumor Biol.* 31, 633–641. <https://doi.org/10.1007/s13277-010-0079-8>
- Riedl, J., Posch, F., Königsbrügge, O., Lötsch, F., Reitter, E.M., Eigenbauer, E., Marosi, C., Schwarzinger, I., Zielinski, C., Pabinger, I., Ay, C., 2014. Red cell distribution width and other red blood cell parameters in patients with cancer: Association with risk of venous thromboembolism and mortality. *PLoS One* 9, 1–14. <https://doi.org/10.1371/journal.pone.0111440>
- Ringehan, M., McKeating, J., Protzer, U., 2017. Viral hepatitis and liver cancer. *Philos. Trans. R. Soc. B Biol. Sci.* 372, 20160274. <https://doi.org/10.1098/rstb.2016.0274>
- Rosner, M.H., Dalkin, A.C., 2014. Electrolyte Disorders Associated With Cancer. *Adv. Chronic Kidney Dis.* 21, 7–17. <https://doi.org/10.1053/j.ackd.2013.05.005>

- Ruggieri, A., Barbati, C., Malorni, W., 2010. Cellular and molecular mechanisms involved in hepatocellular. *Int. J. Cancer* 127, 499–504. <https://doi.org/10.1002/ijc.25298>
- Serag, H.B.E.L., Rudolph, K.L., 2007. Reviews in basic and clinical gastroenterology. *Gastroenterology* 132, 2557–2576. <https://doi.org/10.1053/j.gastro.2007.04.061>
- Shirali, A.C., 2016. Chapter 5: Electrolyte and Acid – Base Disorders in Malignancy. *Am. J. Med.* 1–7.
- Sieghart, W., Pinter, M., Hucke, F., Graziadei, I., Schöniger-Hekele, M., Müller, C., Vogel, W., Trauner, M., Peck-Radosavljevic, M., 2013. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. *Hepatology* 57, 2224–2234. <https://doi.org/10.1002/hep.26057>
- Sinn, D.H., Gwak, G., Cho, J., Paik, S.W., Yoo, B.C., 2014. Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related. *PLoS One* 9, 1–9. <https://doi.org/10.1371/journal.pone.0112184>
- Siregar, G.A., Buulolo, B.A., 2018. Factors associated with tumor size of hepatocellular carcinoma. *IOP Conf. Ser. Earth Environ. Sci.* 125, 1–6.
- Strayer, D.S., Rubin, E., Saffitz, J.E., Schiller, A.L., 2015. Rubin's Pathology: Clinicopathologic Foundations of Medicine 7th Edition.
- Thapa, B.R., Walia, A., 2007. Liver Function Tests and their Interpretation. *Indian J. Pediatr.* 74, 663–671.
- Thrall, M.J., Giampoli, E.J., 2009. Routine review of ascites fluid from patients with cirrhosis or hepatocellular carcinoma is a low-yield procedure: an observational study. *Cytojournal* 6, 1–5. <https://doi.org/10.4103/1742-6413.54919>
- Tripodi, A., Chantarangkul, V., Primignani, M., Fabris, F., Era, A.D., Sei, C., Mannucci, P.M., 2007. The International Normalized Ratio Calibrated for Cirrhosis (INRliver) Normalizes Prothrombin Time Results for Model for End-Stage Liver Disease Calculation. *Hepatology* 46, 520–527. <https://doi.org/10.1002/hep.21732>
- Wada, H., Usui, M., Sakuragawa, N., 2008. Hemostatic Abnormalities and Liver Diseases. *Semin. Thromb. Hemost.* 34, 772–778. <https://doi.org/10.1055/s-0029-1145259>
- Wands, J., 2007. clinical implications of basic research Hepatocellular Carcinoma and Sex. *N. Engl. J. Med.* 357, 1974–1976.
- Wang, B., Ma, W., Sulaiman, A., Noer, S., Sumoharjo, S., Sumarsidi, D., Tandon, B.N., Nakao, K., Mishiro, S., 2002. Demographic, Clinical, and Virological Characteristics of Hepatocellular Carcinoma in Asia: Survey of 414 Patients From Four Countries. *J. Med. Virol.* 67, 394–400. <https://doi.org/10.1002/jmv.10087>
- Wei, T., Tang, Q., Qin, B., Ma, N., Wang, L., Zhou, L., Zhong, R., 2016. Elevated red blood cell distribution width is associated with liver function tests in

- patients with primary hepatocellular carcinoma. *Clin. Hemorheol. Microcirc.* 64, 149–155. <https://doi.org/10.3233/CH-162053>
- Wong, M.C.S., Jiang, J.Y., Goggins, W.B., Liang, M., Fang, Y., Fung, F.D.H., Leung, C., Wang, H.H.X., Wong, G.L.H., Wong, V.W.S., Chan, H.L.Y., 2017. International incidence and mortality trends of liver cancer: a global profile. *Sci. Rep.* 7, 45846. <https://doi.org/10.1038/srep45846>
- Wu, W., He, X., Andayani, D., Yang, L., Ye, J., Li, Y., Chen, Y., Li, L., 2017. Pattern of distant extrahepatic metastases in primary liver cancer: A SEER based study. *J. Cancer* 8, 2312–2318. <https://doi.org/10.7150/jca.19056>
- Xiao, G.-Q., Liu, C., Liu, D.-L., Yang, J.-Y., Yan, L.-N., 2013. Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation. *World J. Gastroenterol.* 19, 8398. <https://doi.org/10.3748/wjg.v19.i45.8398>
- Xie, X., Yao, M., Chen, X., Lu, W., Lv, Q., Wang, K., Zhang, L., Lu, F., 2015. Reduced Red Blood Cell Count Predicts Poor Survival After Surgery in Patients With Primary Liver Cancer. *Med.* 94, 1–8. <https://doi.org/10.1097/MD.0000000000000577>
- Yeung, R.T., 1997. Hypoglycaemia in hepatocellular carcinoma: a review. *Hong Kong Med. J.* 3, 297–301.
- Yi, S., Choi, J.-S., Yi, J.-J., Lee, Y.-H., Jun Han, K., 2018. Risk Factors for Hepatocellular Carcinoma by Age , Sex , and Liver Disorder Status : A Prospective Cohort Study in Korea. *Cancer* 124, 2748–2757. <https://doi.org/10.1002/cncr.31406>
- Yuan, J., Liang, H., Li, J., Li, M., Tang, B., Ma, H., Xie, X., Yin, X., Zhang, L., Ren, Z., 2017. Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib. *Mol. Clin. Oncol.* 7, 837–842. <https://doi.org/10.3892/mco.2017.1416>
- Zhao, Y.-J., Ju, Q., Li, G.-C., 2013. Tumor markers for hepatocellular carcinoma (Review). *Mol. Clin. Oncol.* 1, 593–598. <https://doi.org/10.3892/mco.2013.119>